Benign breast disease (BBD) diagnosed from the second screening onward is associated with a "significantly higher" subsequent risk of breast cancer than BBD diagnosed on the first screening, Dr. Marta Roman of Hospital del Mar Medical Research Institute in Barcelona reported October 2 during a virtual presentation to the 12th European Breast Cancer Conference (EBCC12).
This finding "should be considered when discussing risk-based personalized screening strategies," said Dr. Roman.
In a statement, conference co-chair Dr. Javier Cortes, with Vall d'Hebron Institute of Oncology, also in Barcelona, said, "The results from this study provide us with useful information that can improve the accuracy of breast cancer risk prediction models so that we can tailor surveillance strategies for patients with this disease."
The study team assessed differences in risk of breast cancer after diagnosis of prevalent BBD detected on the first (baseline) mammography screening or incident BBD detected on subsequent screenings. They had data for 629,087 women who underwent more than 2.3 million screening mammograms between 1995 and 2015 and were followed until 2017.
In adjusted models, compared with women with no BBD, women with incident BBD had a 2.67-fold increased chance of developing breast cancer, which was significantly higher than the increase in women with prevalent BBD (adjusted hazard ratio, 1.87).
In addition, women with proliferative BBD had a 3.28-fold increased risk of breast cancer compared with women with no BBD, while women with non-proliferative BBD had a 1.96-fold increased risk.
The highest risk of subsequent breast cancer was in women with incident, proliferative BBD with atypia, with a 4.35-fold increased risk.
"Clinicians involved in the management of women with BBD could offer targeted surveillance strategies considering, in addition to other factors, if the BBD was found at first or in subsequent screening examinations," study chief Dr. Xavier Castells of Hospital del Mar said in the statement.
By Megan Brooks
SOURCE: https://bit.ly/36pumFU 12th European Breast Cancer Conference, presented October 2, 2020.
Posted on
Previous Article
« Predictive sensorimotor control largely preserved in autism Next Article
Quality of life appears to suffer little when adding radiation to androgen deprivation for prostate cancer »
« Predictive sensorimotor control largely preserved in autism Next Article
Quality of life appears to suffer little when adding radiation to androgen deprivation for prostate cancer »
Related Articles
November 19, 2021
Meta-analysis shows 6-months adjuvant trastuzumab is optimal
January 11, 2024
Pregnancy is not contraindicated in pathogenic BRCA carriers
November 19, 2021
Postmenopausal breast cancer: extended letrozole reduces recurrence
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com